Gastric cancer, version 2.2013

Jaffer A. Ajani; David J. Bentrem; Stephen Besh; Thomas A. D'Amico; Prajnan Das; Crystal Denlinger; Marwan G. Fakih; Charles S. Fuchs; Hans Gerdes; Robert E. Glasgow; James A. Hayman; Wayne L. Hofstetter; David H. Ilson; Rajesh N. Keswani; Lawrence R. Kleinberg; W. Michael Korn; A. Craig Lockhart; Kenneth Meredith; Mary F. Mulcahy; Mark B. Orringer; James A. Posey; Aaron R. Sasson; Walter J. Scott; Vivian E. Strong; Thomas K. Varghese; Graham Warren; Mary Kay Washington; Christopher Willett; Cameron D. Wright; Nicole R. McMillian; Hema Sundar

doi:10.6004/jnccn.2013.0070

Gastric cancer, version 2.2013

Jaffer A. Ajani, David J. Bentrem, Stephen Besh, Thomas A. D'Amico, Prajnan Das, Crystal Denlinger, Marwan G. Fakih, Charles S. Fuchs, Hans Gerdes, Robert E. Glasgow, James A. Hayman, Wayne L. Hofstetter, David H. Ilson, Rajesh N. Keswani, Lawrence R. Kleinberg, W. Michael Korn, A. Craig Lockhart, Kenneth Meredith, Mary F. Mulcahy, Mark B. OrringerJames A. Posey, Aaron R. Sasson, Walter J. Scott, Vivian E. Strong, Thomas K. Varghese, Graham Warren, Mary Kay Washington, Christopher Willett, Cameron D. Wright, Nicole R. McMillian, Hema Sundar

Surgical Oncology

Research output: Contribution to journal › Article › peer-review

451 Scopus citations

Abstract

The NCCN Clinical Practice Guidelines in Oncology for Gastric Cancer provide evidence- and consensus-based recommendations for a multidisciplinary approach for the management of patients with gastric cancer. For patients with resectable locoregional cancer, the guidelines recommend gastrectomy with a D1+ or a modified D2 lymph node dissection (performed by experienced surgeons in high-volume centers). Postoperative chemoradiation is the preferred option after complete gastric resection for patients with T3-T4 tumors and node-positive T1-T2 tumors. Postoperative chemotherapy is included as an option after a modified D2 lymph node dissection for this group of patients. Trastuzumab with chemotherapy is recommended as first-line therapy for patients with HER2-positive advanced or metastatic cancer, confirmed by immunohistochemistry and, if needed, by fluorescence in situ hybridization for IHC 2+.

Original language	English (US)
Pages (from-to)	531-546
Number of pages	16
Journal	JNCCN Journal of the National Comprehensive Cancer Network
Volume	11
Issue number	5
DOIs	https://doi.org/10.6004/jnccn.2013.0070
State	Published - May 1 2013

ASJC Scopus subject areas

Oncology

Access to Document

10.6004/jnccn.2013.0070

Cite this

Ajani, J. A., Bentrem, D. J., Besh, S., D'Amico, T. A., Das, P., Denlinger, C., Fakih, M. G., Fuchs, C. S., Gerdes, H., Glasgow, R. E., Hayman, J. A., Hofstetter, W. L., Ilson, D. H., Keswani, R. N., Kleinberg, L. R., Korn, W. M., Lockhart, A. C., Meredith, K., Mulcahy, M. F., ... Sundar, H. (2013). Gastric cancer, version 2.2013. JNCCN Journal of the National Comprehensive Cancer Network, 11(5), 531-546. https://doi.org/10.6004/jnccn.2013.0070

Ajani, JA, Bentrem, DJ, Besh, S, D'Amico, TA, Das, P, Denlinger, C, Fakih, MG, Fuchs, CS, Gerdes, H, Glasgow, RE, Hayman, JA, Hofstetter, WL, Ilson, DH, Keswani, RN, Kleinberg, LR, Korn, WM, Lockhart, AC, Meredith, K, Mulcahy, MF, Orringer, MB, Posey, JA, Sasson, AR, Scott, WJ, Strong, VE, Varghese, TK, Warren, G, Washington, MK, Willett, C, Wright, CD, McMillian, NR & Sundar, H 2013, 'Gastric cancer, version 2.2013', JNCCN Journal of the National Comprehensive Cancer Network, vol. 11, no. 5, pp. 531-546. https://doi.org/10.6004/jnccn.2013.0070

@article{b7f9da81e5a74f96927bd273c508af20,

title = "Gastric cancer, version 2.2013",

abstract = "The NCCN Clinical Practice Guidelines in Oncology for Gastric Cancer provide evidence- and consensus-based recommendations for a multidisciplinary approach for the management of patients with gastric cancer. For patients with resectable locoregional cancer, the guidelines recommend gastrectomy with a D1+ or a modified D2 lymph node dissection (performed by experienced surgeons in high-volume centers). Postoperative chemoradiation is the preferred option after complete gastric resection for patients with T3-T4 tumors and node-positive T1-T2 tumors. Postoperative chemotherapy is included as an option after a modified D2 lymph node dissection for this group of patients. Trastuzumab with chemotherapy is recommended as first-line therapy for patients with HER2-positive advanced or metastatic cancer, confirmed by immunohistochemistry and, if needed, by fluorescence in situ hybridization for IHC 2+.",

author = "Ajani, {Jaffer A.} and Bentrem, {David J.} and Stephen Besh and D'Amico, {Thomas A.} and Prajnan Das and Crystal Denlinger and Fakih, {Marwan G.} and Fuchs, {Charles S.} and Hans Gerdes and Glasgow, {Robert E.} and Hayman, {James A.} and Hofstetter, {Wayne L.} and Ilson, {David H.} and Keswani, {Rajesh N.} and Kleinberg, {Lawrence R.} and Korn, {W. Michael} and Lockhart, {A. Craig} and Kenneth Meredith and Mulcahy, {Mary F.} and Orringer, {Mark B.} and Posey, {James A.} and Sasson, {Aaron R.} and Scott, {Walter J.} and Strong, {Vivian E.} and Varghese, {Thomas K.} and Graham Warren and Washington, {Mary Kay} and Christopher Willett and Wright, {Cameron D.} and McMillian, {Nicole R.} and Hema Sundar",

year = "2013",

month = may,

day = "1",

doi = "10.6004/jnccn.2013.0070",

language = "English (US)",

volume = "11",

pages = "531--546",

journal = "JNCCN Journal of the National Comprehensive Cancer Network",

issn = "1540-1405",

publisher = "Cold Spring Publishing LLC",

number = "5",

}

TY - JOUR

T1 - Gastric cancer, version 2.2013

AU - Ajani, Jaffer A.

AU - Bentrem, David J.

AU - Besh, Stephen

AU - D'Amico, Thomas A.

AU - Das, Prajnan

AU - Denlinger, Crystal

AU - Fakih, Marwan G.

AU - Fuchs, Charles S.

AU - Gerdes, Hans

AU - Glasgow, Robert E.

AU - Hayman, James A.

AU - Hofstetter, Wayne L.

AU - Ilson, David H.

AU - Keswani, Rajesh N.

AU - Kleinberg, Lawrence R.

AU - Korn, W. Michael

AU - Lockhart, A. Craig

AU - Meredith, Kenneth

AU - Mulcahy, Mary F.

AU - Orringer, Mark B.

AU - Posey, James A.

AU - Sasson, Aaron R.

AU - Scott, Walter J.

AU - Strong, Vivian E.

AU - Varghese, Thomas K.

AU - Warren, Graham

AU - Washington, Mary Kay

AU - Willett, Christopher

AU - Wright, Cameron D.

AU - McMillian, Nicole R.

AU - Sundar, Hema

PY - 2013/5/1

Y1 - 2013/5/1

N2 - The NCCN Clinical Practice Guidelines in Oncology for Gastric Cancer provide evidence- and consensus-based recommendations for a multidisciplinary approach for the management of patients with gastric cancer. For patients with resectable locoregional cancer, the guidelines recommend gastrectomy with a D1+ or a modified D2 lymph node dissection (performed by experienced surgeons in high-volume centers). Postoperative chemoradiation is the preferred option after complete gastric resection for patients with T3-T4 tumors and node-positive T1-T2 tumors. Postoperative chemotherapy is included as an option after a modified D2 lymph node dissection for this group of patients. Trastuzumab with chemotherapy is recommended as first-line therapy for patients with HER2-positive advanced or metastatic cancer, confirmed by immunohistochemistry and, if needed, by fluorescence in situ hybridization for IHC 2+.

AB - The NCCN Clinical Practice Guidelines in Oncology for Gastric Cancer provide evidence- and consensus-based recommendations for a multidisciplinary approach for the management of patients with gastric cancer. For patients with resectable locoregional cancer, the guidelines recommend gastrectomy with a D1+ or a modified D2 lymph node dissection (performed by experienced surgeons in high-volume centers). Postoperative chemoradiation is the preferred option after complete gastric resection for patients with T3-T4 tumors and node-positive T1-T2 tumors. Postoperative chemotherapy is included as an option after a modified D2 lymph node dissection for this group of patients. Trastuzumab with chemotherapy is recommended as first-line therapy for patients with HER2-positive advanced or metastatic cancer, confirmed by immunohistochemistry and, if needed, by fluorescence in situ hybridization for IHC 2+.

UR - http://www.scopus.com/inward/record.url?scp=84877995643&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84877995643&partnerID=8YFLogxK

U2 - 10.6004/jnccn.2013.0070

DO - 10.6004/jnccn.2013.0070

M3 - Article

C2 - 23667204

AN - SCOPUS:84877995643

SN - 1540-1405

VL - 11

SP - 531

EP - 546

JO - JNCCN Journal of the National Comprehensive Cancer Network

JF - JNCCN Journal of the National Comprehensive Cancer Network

IS - 5

ER -

Gastric cancer, version 2.2013

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this